(21174) Relative bioavailability study to investigate the pharmacokinetics of a single oral dose of asundexian administered as 50 mg pediatric formulation in comparison to 50 mg tablet (adult formulation) in fasted state and to investigate the effect of a high-fat, high-calorie meal on the 50 mg pediatric formulation in healthy adult participants - 21174
Latest Information Update: 19 Mar 2026
At a glance
- Drugs Asundexian (Primary)
- Indications Stroke; Thromboembolism
- Focus Pharmacokinetics
- Sponsors Bayer
Most Recent Events
- 19 Mar 2026 New trial record